29876-14-0

Basic information

• Product Name: Nicotredole
• Synonyms: Nicotredole;tryptamide;N-(2-(1H-Indol-3-yl)ethyl)nicotinaMide
• CAS NO: 29876-14-0
• Molecular Formula: C₁₆H₁₅N₃O
• Molecular Weight: 265.315
• Mol File: 29876-14-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 408.53°C (rough estimate)
• Flash Point: 309.7°C
• Appearance: /
• Density: 1.0944 (rough estimate)
• Vapor Pressure: 7.96E-14mmHg at 25°C
• Refractive Index: 1.6500 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: Nicotredole(CAS DataBase Reference)
• NIST Chemistry Reference: Nicotredole(29876-14-0)
• EPA Substance Registry System: Nicotredole(29876-14-0)

Safety Data

• Hazardous Substances Data: 29876-14-0(Hazardous Substances Data)

Usage

General Description

Nicotredole is a chemical compound that belongs to the nicotinamide family. It is often used as an intermediate in the synthesis of pharmaceuticals and also as a reagent in various organic reactions. Nicotredole is known for its anti-inflammatory and antioxidant properties, making it a potential candidate for use in the treatment of inflammatory diseases and conditions. It has also been studied for its potential role in neuroprotection and as a therapeutic agent for certain neurological disorders. Additionally, Nicotredole has been found to have potential applications in the field of cancer research and has shown promising results in preclinical studies.

InChI:InChI=1/C16H15N3O/c20-16(13-4-3-8-17-10-13)18-9-7-12-11-19-15-6-2-1-5-14(12)15/h1-6,8,10-11,19H,7,9H2,(H,18,20)

Upstream product

• 10400-19-8 3-pyridinecarbonyl chloride 
• 61-54-1 tryptamine 
• 20260-53-1 pyridine-3-carbonyl chloride hydrochloride 
• 500-22-1 3-pyridinecarboxaldehyde 
• 78348-28-4 nicotinic acid succinimidyl ester 
• 59-67-6 nicotinic acid 

Downstream Products

• 110187-44-5 1-(3'-Pyridyl)-3,4-dihydro-β-karbolin 

Relevant articles and documents

A tryptamine analog with high affinity to the heart tissues is a potential antiarrhythmic agent

A novel tryptamine analog, 1-methyl-3-[N-(3-indolyl)ethyl]carbamoyl-1,4-dihydropyridine (T-CDS) was synthesized and converted into a stable, solid complex with 2-hydroxypropyl-β-cyclodextrin. An aqueous solution of the complex was given intravenously to dogs and the concentration of T-CDS and its corresponding quaternary (T-Q+) forms were monitored in the blood for 50 min. The effect of the drug on vital heart parameters was monitored throughout the studies. At the end of the experiment the dogs were sacrificed and the concentration of the quaternary pyridinium form (T-Q+) was determined in the different heart tissues, as well as in the kidney, liver, lung, brain, urine and cerebrospinal fluid. The compound was found to be selectively bound to the heart muscles and showed different concentrations in different heart tissues. The T-Q+ concentrations were much higher in the heart after administration of the dihydro form (T-CDS), than after administering T-Q+ directly. The compound was found to be active on certain vital signs of the cardiovascular system and could be an effective and safe antiarrhythmic agent.

Aryl substituted amide compounds and its preparation method, pharmaceutical composition containing the same and application thereof (by machine translation)

The invention relates to an aryl-substituted amide compound in the formula (I), a preparing method thereof, a medicine composition comprising the same, and application of the amide compound and the medicine composition to pharmacy, wherein Arl, L1, M1, M2, L2 and Ar2 are defined as in the text. The aryl-substituted amide compound can excite TRPV1 and nuclear receptors (LXRs, PPARs and RXR), adjust expression of cholesterol excretion gap-associated protein ABCA1/G1, SR-BI, adjust expression of inflammation gap-associated protein TNF-alpha and the like, and play roles in promoting excretion of cholesterol and lipid, reducing sugar, adjusting blood lipid, resisting inflammation and reducing blood pressure, and can be used for treating and/or preventing and/or relieving cardiovascular and cerebrovascular diseases, adjusting blood lipid, and resisting atherosclerosis, diabetes mellitus, inflammation, pain and hypertension.

Optimization of rutaecarpine as ABCA1 up-regulator for treating atherosclerosis

ATP-binding cassette transporter A1 (ABCA1) is a key transporter and receptor in promoting cholesterol efflux, and increasing the expression level of ABCA1 is antiatherogenic. In our previous study, rutaecarpine (RUT) was found to protect ApoE-/- mice from developing atherosclerosis through preferentially up-regulating ABCA1 expression. In the present work, a series of RUT derivatives were synthesized and examined as ABCA1 expression up-regulators. Compounds CD1, CD6, and BCD1-2 were found to possess the most potential activity as antiatherosclerotic agents among all compounds tested.